How should I evaluate and treat a patient with triple‑negative breast cancer?

Approach to Triple-Negative Breast Cancer

For newly diagnosed triple-negative breast cancer, immediately obtain a biopsy to confirm histology, assess PD-L1 status, and test for germline BRCA1/2 mutations, as these biomarkers directly determine treatment selection between immunotherapy-chemotherapy combinations, PARP inhibitors, or chemotherapy alone. 1, 2

Initial Diagnostic Workup

Essential Biomarker Testing

• Confirm triple-negative status (ER-negative, PR-negative, HER2-negative) via immunohistochemistry on biopsy tissue 1, 3
• PD-L1 testing by immunohistochemistry is mandatory using FDA-approved assays, as PD-L1 positivity (CPS ≥10) qualifies patients for pembrolizumab combination therapy with significantly improved survival 1, 2, 3
• Germline BRCA1/2 mutation testing must be performed at diagnosis, as BRCA-mutated patients benefit from PARP inhibitors (olaparib) in both adjuvant and metastatic settings 1, 2, 3
• Consider PALB2 assessment as an optional biomarker with emerging therapeutic relevance 1, 2
• Assess Ki-67 proliferation index and histological grade to gauge tumor aggressiveness 4

Staging Evaluation

• Minimum imaging includes CT chest/abdomen and bone scintigraphy, or alternatively 18F-FDG PET-CT may replace both modalities 1
• Use the same imaging modality throughout treatment to ensure accurate response assessment 1
• Breast MRI is the most accurate modality for evaluating tumor extent and response to neoadjuvant therapy 3

Treatment Approach by Stage

Stage I (Small Tumors <5mm)

• Surgical excision alone may be appropriate for very small tumors, though approximately half of experts still recommend adjuvant chemotherapy even for these minimal tumors 2, 5
• Sentinel lymph node biopsy is standard for clinically node-negative patients 2, 5

Stage II-III (Non-Metastatic Disease)

Neoadjuvant chemotherapy with pembrolizumab is the preferred standard approach rather than upfront surgery, as it allows tumor downstaging and provides prognostic information based on pathologic response 2, 3, 5

Preferred Neoadjuvant Regimen (KEYNOTE-522 Protocol)

• Pembrolizumab plus chemotherapy backbone consisting of taxanes + carboplatin + anthracyclines + cyclophosphamide throughout the neoadjuvant phase 2
• The benefit from pembrolizumab is independent of PD-L1 status in the neoadjuvant setting, and carboplatin benefit is independent of germline BRCA1/2 status 2
• Dose-dense anthracycline and taxane combinations achieve pathological complete response rates exceeding 20% 2, 5

Post-Neoadjuvant Surgery

• Perform surgery after completion of neoadjuvant chemotherapy, with breast-conserving surgery preferred if adequate tumor downstaging achieved 2, 5
• Mastectomy is indicated when breast conservation would result in poor cosmetic outcome or when adequate margins cannot be achieved 2, 5
• For patients with clinically positive nodes who become clinically negative after neoadjuvant therapy, sentinel lymph node biopsy may be considered 2, 5
• Axillary lymph node dissection is recommended for residual nodal disease after neoadjuvant therapy, especially for macrometastases >2mm 2, 5

Adjuvant Therapy After Surgery

• Continue adjuvant pembrolizumab to complete the full treatment course, regardless of pathologic response (pCR vs. residual disease) 2
• For patients with germline BRCA1/2 mutations and high-risk disease, add adjuvant olaparib for 1 year after completion of chemotherapy and surgery 2, 5
• Pathologic complete response (pCR) is a strong prognostic indicator regardless of BRCA status 2

Radiation Therapy

• Post-lumpectomy radiation to the breast is standard after breast-conserving surgery 2, 3, 5
• Post-mastectomy radiation therapy (PMRT) is indicated for positive lymph nodes, positive or close surgical margins 2, 3, 5
• Consider PMRT for stage IIB disease based on nodal burden 2
• For patients with clinically node-positive disease at baseline with residual nodal involvement, comprehensive regional nodal radiation including level 1-3 axillary nodes, supraclavicular nodes, and internal mammary nodes is recommended 3
• Radiation decisions should be based on initial tumor stage at presentation and baseline nodal status, not solely on post-neoadjuvant pathologic findings 3

Special Surgical Considerations

• Do not routinely recommend prophylactic contralateral mastectomy based solely on TNBC status 2, 5
• Consider bilateral mastectomy for germline BRCA1/2 mutations, very young age at diagnosis, or strong family history after thorough counseling 2, 5
• Delayed reconstruction may be more appropriate than immediate reconstruction in TNBC patients likely to require post-mastectomy radiation 2, 5

Stage IV (Metastatic Disease)

Re-biopsy metastatic lesions when technically feasible to confirm histology and reassess biomarkers, as tumor biology may change from primary to metastatic disease 1, 3

First-Line Treatment Algorithm

For PD-L1-positive disease (CPS ≥10):

• Pembrolizumab plus chemotherapy is the preferred first-line regimen, providing significant survival benefit with median OS of 23.0 versus 16.1 months (HR 0.73; P=0.0093) 3, 6
• Atezolizumab plus albumin-bound paclitaxel is an alternative, demonstrating improved PFS (7.5 vs 5 months; HR 0.62) and OS (25 vs 15.5 months; HR 0.62) in PD-L1-positive tumors 3, 6

For germline BRCA1/2-mutated disease:

• PARP inhibitors (olaparib or talazoparib) are preferred over chemotherapy in the first-through third-line setting, with median PFS of 7.0 months vs 4.2 months with chemotherapy (HR 0.58; P<0.001) for olaparib 3, 6
• Platinum agents (cisplatin or carboplatin) are preferred alternatives if PARP inhibitors are unavailable, with carboplatin showing superiority over docetaxel in BRCA-mutated patients (ORR 68.0% vs 33.3%; P=0.03) 3

For PD-L1-negative disease without BRCA mutations:

• Single-agent chemotherapy is preferred to minimize toxicity 3
• Taxanes (paclitaxel or docetaxel) are preferred first-line options if not previously used in the adjuvant setting 3
• Anthracyclines are recommended if not previously administered 3
• Combination chemotherapy may be offered only for symptomatic or immediately life-threatening disease where time may allow only one potential chance for therapy 3

Second-Line and Beyond

• For patients who have received at least two prior therapies for metastatic disease, sacituzumab govitecan is strongly recommended, with significant improvements in both progression-free survival and overall survival 3, 6
• Alternative second-line options include platinum agents (if not previously used), capecitabine, eribulin, and gemcitabine 3
• Immune checkpoint inhibitors may be considered as monotherapy in further lines in case of high PD-L1 positivity and no previous exposure to ICI 3

Treatment Duration and Monitoring

• Continue chemotherapy until disease progression or limiting toxicities 3
• Patients receiving checkpoint inhibitors must be monitored closely for immune-related adverse events, which can affect any organ system 3
• Maintain the same imaging modality chosen at baseline for disease monitoring to ensure comparability 1

Critical Pitfalls to Avoid

• Do not withhold chemotherapy based on high TIL levels in early-stage TNBC, as there is lack of prognostic information for patients not treated with chemotherapy 1
• Do not delay biomarker testing (PD-L1, BRCA1/2) as these directly determine treatment eligibility for life-prolonging therapies 1, 2, 3
• Do not use bevacizumab routinely, as it has shown improved progression-free survival but not overall survival, limiting its recommendation 3
• Do not base radiation decisions solely on post-neoadjuvant pathologic findings; consider initial tumor stage at presentation and baseline nodal status 3